LB003-MON ORAL NUTRACEUTICAL FORMULA (PLP10) FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS: DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Double Blind ◽

Relapsing Remitting ◽

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: A double blind randomized clinical trial

Clinical Neurology and Neurosurgery ◽

10.1016/j.clineuro.2012.02.039 ◽

2012 ◽

Vol 114 (7) ◽

pp. 986-989 ◽

Cited By ~ 8

Author(s):

Shahriar Nafissi ◽

Amirreza Azimi ◽

Ali Amini-Harandi ◽

Shiva Salami ◽

Mohammad Amir shahkarami ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Side Effects ◽

Interferon Beta ◽

Double Blind ◽

Relapsing Remitting ◽

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial

Frontiers in Behavioral Neuroscience ◽

10.3389/fnbeh.2016.00028 ◽

2016 ◽

Vol 10 ◽

Cited By ~ 11

Author(s):

Flavia Mattioli ◽

Fabio Bellomi ◽

Chiara Stampatori ◽

Leandro Provinciali ◽

Laura Compagnucci ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Cognitive Training ◽

Domain Specific ◽

Relapsing Remitting ◽

A non‐randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing‐remitting multiple sclerosis patients

Clinical and Translational Medicine ◽

10.1186/s40169-019-0228-7 ◽

2019 ◽

Vol 8 (1) ◽

Author(s):

Mehrdokht Mazdeh ◽

Shahriar Kargar Monhaser ◽

Mohammad Taheri ◽

Soudeh Ghafouri‐Fard

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Scale Score ◽

Expanded Disability Status Scale ◽

Disability Status ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis – Randomized clinical trial

PLoS ONE ◽

10.1371/journal.pone.0230551 ◽

2020 ◽

Vol 15 (4) ◽

pp. e0230551

Author(s):

Tamiris Silva ◽

Yara Dadalti Fragoso ◽

Maria Fernanda Setúbal Destro Rodrigues ◽

Andréa Oliver Gomes ◽

Fernanda Cordeiro da Silva ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Interleukin 10 ◽

Relapsing Remitting ◽

Pioneer oral nutraceutical formula (PLP10) for the treatment of relapsing remitting multiple sclerosis: A randomized, double-blind, placebo-controlled proof-of-concept clinical trial

PharmaNutrition ◽

10.1016/j.phanu.2013.11.038 ◽

2014 ◽

Vol 2 (3) ◽

pp. 88

Author(s):

I.S. Patrikios ◽

G.N. Loukaides ◽

E.E. Ntzani ◽

M.C. Pantzaris

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial

American Journal of Clinical Nutrition ◽

10.3945/ajcn.113.075309 ◽

2015 ◽

Vol 101 (3) ◽

pp. 487-495 ◽

Cited By ~ 30

Author(s):

Anja Mähler ◽

Jochen Steiniger ◽

Markus Bock ◽

Lars Klug ◽

Nadine Parreidt ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Metabolic Response ◽

Relapsing Remitting ◽

RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

Neuromuscular Diseases ◽

10.17650/2222-8721-2016-6-4-28-36 ◽

2016 ◽

Vol 6 (4) ◽

pp. 28-36 ◽

Cited By ~ 3

Author(s):

F. A. Khabirov ◽

T. I. Khaibullin ◽

E. V. Granatov ◽

N. N. Babicheva ◽

L. A. Aver’yanova ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Open Label ◽

Relapsing Remitting ◽

Pharmaceutical Industries ◽

The effects of modified anti-inflammatory diet on fatigue, quality of life, and inflammatory biomarkers in relapsing-remitting multiple sclerosis patients: a randomized clinical trial

International Journal of Neuroscience ◽

10.1080/00207454.2020.1750398 ◽

2020 ◽

pp. 1-9

Author(s):

Zahra Mousavi-Shirazi-Fard ◽

Zohreh Mazloom ◽

Sadegh Izadi ◽

Mohammad Fararouei

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Clinical Trial ◽

Inflammatory Biomarkers ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Efficacy and Safety of Temelimab, an Antibody Antagonist of the Human Endogenous Retrovirus Type-W env Protein, in Participants with Relapsing Remitting Multiple Sclerosis: A Double-Blind, Randomised, Placebo-Controlled Phase 2b Clinical Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3388820 ◽

2019 ◽

Author(s):

Hans-Peter Hartung ◽

Tobias Derfuss ◽

Bruce Cree ◽

Maria Pia Sormani ◽

Krzysztof Selmaj ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Endogenous Retrovirus ◽

Human Endogenous Retrovirus ◽

Efficacy And Safety ◽

Double Blind ◽

Relapsing Remitting ◽

Env Protein ◽

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽